Skip to main content
Clinical Trials/JPRN-jRCTs032200164
JPRN-jRCTs032200164
Completed
Phase 2

Verification of reduction on upper limb spasticity by applying Jiggling motion

Abo Masahiro0 sites140 target enrollmentOctober 19, 2020

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Abo Masahiro
Enrollment
140
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 19, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Abo Masahiro

Eligibility Criteria

Inclusion Criteria

  • Targetting patients with upper limb spasticity as a result of aftereffects of stroke,
  • and who meet all of the following criteria, and who can obtain their consent;
  • 1\)Stroke sequelae patients with upper extremity spasticity between the ages of 20 and 80
  • 2\)More than 6 months have passed since the onset of stroke
  • 3\)Upper limb Brunstrom stage, which is an upper limb function evaluation, is 3\-5
  • 4\)The general condition is stable
  • 5\)Patients who do not recognize cognitive impairment and can understand the research plan
  • 6\)Patients who received a sufficient explanation to participate in this study and, after a thorough understanding, obtained the written informed consent of the patient.
  • 7\)Regardless of gender
  • 8\)Patients who can visit the hospital according to the study schedule

Exclusion Criteria

  • Those who meet at least one of the following exclusion criteria will be excluded.
  • 1\)Patients with implantable medical devices (pacemakers or cochlear implants)
  • 2\) Patients with serious heart disease
  • 3\) Pregnant women or patients suspected of being pregnant
  • 4\) In addition, patients who are judged to be inappropriate to participate in this study by research responsible doctors or assigned doctors
  • 5\) Patients who are unstable or need immediate treatment (acute heart failure, acute renal failure, acute liver failure, severe diabetes, infectious disease, etc.)
  • 6\) Patients who participated in other clinical trials within 4 months

Outcomes

Primary Outcomes

Not specified

Similar Trials